Don Manvel of Birmingham Elected to Karmanos Cancer Institute Board of Directors
The Barbara Ann Karmanos Cancer Institute (KCI) is pleased to announce the election of Don Manvel to its Board of Directors. Manvel will serve a three-year term.
Members of the KCI board are dedicated to providing strategic direction as Karmanos moves toward the goal of serving as one of the nation’s top 10 National Cancer Institute-designated comprehensive cancer centers.
Manvel is chairman and CEO of the North American operations of AVL, the recognized leader in developing clean and efficient technologies to fuel the world. Under his leadership, AVL Americas has grown significantly on this continent, becoming well known for the next-generation technological and engineering solutions it provides for its blue-chip OEM customers.
Prior to joining AVL, Manvel held a variety of senior executive positions in various parts of the world. He worked closely with Dean Kamen, founder of Segway Inc., on the development of the first self-balancing, electronic transportation device – the Segway Human Transporter. While at the former Chrysler Corp., he was a member of the group that engineered the successful bailout and turnaround of this automotive icon. He also helped orchestrate the merger of Daimler and Chrysler in South America and was responsible for helping make Jeep Grand Cherokee one of the company’s leading global brands.
Manvel holds a master’s of business administration from Wayne State University. He is a passionate advocate of organizations that are searching for a cancer cure, as well as educational and technological groups and foundations. Manvel, a well-known patron of the Greater Detroit community, resides in Birmingham.
About the Barbara Ann Karmanos Cancer Institute Located in mid-town Detroit, Michigan, the Barbara Ann Karmanos Cancer Institute is one of 41 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for nearly 6,000 new patients annually on a budget of $265 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, Karmanos is among the nation’s best cancer centers. Through the commitment of 1,000 staff, including nearly 300 physicians and researchers on faculty at the Wayne State University School of Medicine, and supported by thousands of volunteer and financial donors, Karmanos strives to prevent, detect and eradicate all forms of cancer. Its long-term partnership with the WSU School of Medicine enhances the collaboration of critical research and academics related to cancer care. Gerold Bepler, M.D., Ph.D., is the Institute’s president and chief executive officer. For more information call 1-800-KARMANOS or go to www.karmanos.org.